A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

* Chronic hepatitis C, genotype 1b-infection (HCV RNA level greater than 1,000 IU/mL at Screening) * Evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with Child-Pugh score less than or equal to 6 at Screening * Participant had never received antiviral treatment (including pegIFN/RBV) for hepatitis C infection (treatment-naïve participant) or had documentation of meeting one of the defined categories of a treatment-experienced participants * Absence of hepatocellular carcinoma (HCC) as indicated by a negative ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI) performed within 3 months prior to screening or a negative ultrasound at screening. * Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control * Males must have been surgically sterile, or agreed to practice 2 effective methods of birth control throughout the course of the study.

* Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus antibody * Evidence of current or past Child-Pugh B or C classification * Confirmed presence of hepatocellular carcinoma * Abnormal laboratory tests * Participant who self-reported on average drinking more than 2 drinks per day for current drinkers * Previous treatment with a direct acting antiviral agent (DAA) containing regimen * History of solid organ transplant.